These results predicted that RFAs including rhein, diacerein, emodin, aloe emodin, and 1,8-dihydroxyanthraquinone could be regarded as NLRP3 inflammasome blockers to treat NAFLD. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.